# Alexa B. Kimball

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alexa-b-kimball/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,794 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 82 |
| i10-index | 298 |
| Last Known Institution | Beth Israel Deaconess Medical Center |
| OpenAlex ID | https://openalex.org/A5059337854 |
| ORCID iD | 0000-0001-9405-0479 |
| Works | 550 |

## Researcher papers

Showing 12 of 17.

- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody/)
- [Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial](https://scholariq.org/papers/adalimumab-therapy-for-moderate-to-severe-psoriasis-a-randomized-controlled/)
- [Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial](https://scholariq.org/papers/efficacy-and-safety-of-guselkumab-an-anti-interleukin-23-monoclonal-antibody/)
- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa](https://scholariq.org/papers/two-phase-3-trials-of-adalimumab-for-hidradenitis-suppurativa/)
- [IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis](https://scholariq.org/papers/il-23-stimulates-epidermal-hyperplasia-via-tnf-and-il-20r2-dependent-mechanisms/)
- [Hidradenitis suppurativa](https://scholariq.org/papers/hidradenitis-suppurativa-2/)
- [Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials](https://scholariq.org/papers/tildrakizumab-versus-placebo-or-etanercept-for-chronic-plaque-psoriasis/)
- [The Psychosocial Burden of Psoriasis](https://scholariq.org/papers/the-psychosocial-burden-of-psoriasis/)
- [Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity](https://scholariq.org/papers/development-and-validation-of-the-international-hidradenitis-suppurativa/)
- [Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials](https://scholariq.org/papers/secukinumab-in-moderate-to-severe-hidradenitis-suppurativa-sunshine-and-sunrise/)
- [Psoriasis: is the impairment to a patient’s life cumulative?](https://scholariq.org/papers/psoriasis-is-the-impairment-to-a-patient-s-life-cumulative/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Hidradenitis Suppurativa and Treatments](https://scholariq.org/topics/hidradenitis-suppurativa-and-treatments/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)
- [Acne and Rosacea Treatments and Effects](https://scholariq.org/topics/acne-and-rosacea-treatments-and-effects/)

## Researcher university

- [Beth Israel Deaconess Medical Center](https://scholariq.org/institutions/beth-israel-deaconess-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.